In this time of growing trial complexity, the use of patient advisory boards is critical to improving the patient and site trial experience — but just a small fraction of protocols currently use them, according to two WCG experts. Read More
The scope and burden of conducting late-stage trials is rapidly growing, research from Tufts University’s Center for the Study of Drug Development (CSDD) finds, with the average number of phase 3 endpoints having increased 37 percent since 2015. Read More
The increasing trend toward conducting global trials has watered down representation of some U.S. ethnic and racial minorities in drug development, according to one FDA official. Read More
As the pandemic-era lure of decentralized trials (DCT) waned last year and traditional trials reasserted themselves, sites considering sponsors in 2023 are placing critical importance on sponsors’ willingness to accept and integrate site-picked technology. Read More
The two-year transition to the new EU Clinical Trials Regulation (EU-CTR), set to begin Jan. 31, 2023, may be off to a rocky start, according to several experts that attribute much of the concern to the function of the Clinical Trials Information System (CTIS) at the heart of the new regulatory scheme.
The market for CROs, once only niche providers of trial support services, is at an all-time high as sponsors increasingly outsource their clinical trial activities, leading to record levels of CRO consolidation and growth, according to a new analysis. Read More
Machine learning (ML) is viewed as the next generation solution for supporting decision-making and development by many industries, and the clinical research sector is no exception. But not all applications of this artificial intelligence technology are appropriate for clinical trials, say several researchers who have raised questions about its validity, reliability and scalability. Read More
